GMS Ventures & Investments, Director, 10% Owner at Outlook Therapeutics, Inc. (OTLK), bought 8,360,000 shares at $1.00 ($8.4M) on 2021-02-02, disclosed to the SEC on 2021-02-02.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.